# Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue

> **NCT01937312** · PHASE4 · COMPLETED · sponsor: **Alcon Research** · enrollment: 282 (actual)

## Conditions studied

- Ocular Hypertension
- Open Angle Glaucoma

## Interventions

- **DRUG:** Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension
- **DRUG:** Vehicle
- **DRUG:** Prostaglandin analogue

## Key facts

- **NCT ID:** NCT01937312
- **Lead sponsor:** Alcon Research
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-10
- **Primary completion:** 2014-05
- **Final completion:** 2014-05
- **Target enrollment:** 282 (ACTUAL)
- **Last updated:** 2015-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01937312

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01937312, "Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01937312. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*